## **Core Concept**
The question tests knowledge of specific cell surface markers (also known as cluster of differentiation or CD markers) associated with B lymphocytes. B cells, or B lymphocytes, are a type of white blood cell that plays a crucial role in the adaptive immune system by producing antibodies. Different stages of B cell development and activation are characterized by the presence of specific surface markers.

## **Why the Correct Answer is Right**
The correct answer, . **CD19**, is a marker that is expressed on the surface of B cells from the earliest recognizable B-lineage cells during B cell development in the bone marrow, to mature B cells, but it is lost on maturation to plasma cells. CD19 is used as a marker for B cells in various stages of development and is considered a pan-B cell marker.

## **Why Each Wrong Option is Incorrect**
- **Option A:** - This is not a commonly recognized pan-B cell marker.
- **Option B:** - While certain B cells express this marker, it is not universally expressed on all B cells (pan-B cell marker).
- **Option C:** - This option might represent a marker for a subset of B cells or other immune cells but is not a pan-B cell marker.
- **Option D:** - Similarly, this could represent a marker for specific subsets or stages of B cells or other cell types but is not considered a pan-B cell marker.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **CD19** is a reliable marker for diagnosing B cell lymphoproliferative disorders and for monitoring B cell counts in patients undergoing treatments that target B cells, such as Rituximab. This monoclonal antibody targets CD20, another B cell marker, but not CD19.

## **Correct Answer:** . **CD19**